Come up with a name for your new list and we'll add to it:
Aravax raised a round of funding on November 24, 2015. Investors include
Brandon Capital Partners.
Aravax is developing a novel therapy for the treatment of peanut allergy which is anticipated to enter phase I clinical trial in 2016.…